Antibacterial activity of an oral quinolone, balofloxacin, and its clinical effects on respiratory infectious diseases

DOI 9 References

Bibliographic Information

Other Title
  • 経口用キノロン薬balofloxacinの抗菌活性と呼吸器感染症に対する臨床効果

Search this article

Abstract

The in vitro antibacterial activity of a newly developed oral quinolone, balofloxacin (BLFX), and its clinical effects on respiratory infectious diseases were investigated. The antibacterial activity of BLFX against 236 strains of 8 species of clinical isolates tended to be greater for gram-positive bacteria and less for gram-negative bacteria than existing quinolone preparations. When BLFX was orally administered at a dose of 100mg or 200mg twice a day for 6-14 days to 15 patients with respiratory infectious diseases, the clinical efficacy was excellent in 2 and good in 13, for an efficacy rate of 100%. Four strains of gram-positive cocci and 8 strains of gram-negative bacteria were isolated from 10 patients as the causative organisms, and all 12 strains were eradicated. No abnormal changes in clinical laboratory test values and no side effects were observed in any of the patients.<BR>Although BLFX exhibited no marked in vitro antibacterial activity, it exerted clinical efficacy equivalent to existing quinolone. It had no problem with safety. These results suggest that BLFX is useful for the treatment of respiratory infectious diseases.

Journal

References(9)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top